


I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW



DATE: 11/29/01

PATENT

Box Non-Fee Amendment

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re:	Patent Application of Lisbeth ILLUM <i>et al.</i>	: Group Art Unit: 1615
Conf. No.:	2569	:
Appln. No.:	09/834,312	: Examiner: B. Fubara
Filed:	April 13, 2001	:
For:	NOVEL FORMULATIONS OF FEXOFENADINE	: Attorney Docket : No. 8567-603US : (WESR/P21598US)

AMENDMENT

In response to the Office Action mailed August 29, 2001 (Paper No. 5), please consider the following remarks and amendments. This response is timely filed on or before November 29, 2001.

Please amend the application without prejudice as follows:

In the Specification:

Please amend the specification as follows:

Please replace paragraph [0001] of the specification in accordance with 37 C.F.R. §1.121(b)(1) to read as follows, including the changes shown on the attached Marked Up Version of the Specification in which additions are shown by underlining and deletions are shown by bracketing:

[0001] This application is a continuation of International Application No. PCT/GB99/03396, filed October 12, 1999, and published in the English language on April 20, 2001, the disclosure of which is incorporated herein by reference.